# US 2017/0362302 A1 · Method and Pharmaceutical Composition for Use in the Treatment of Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362302 A1
- Document ID: US20170362302A1
- Status: Published application
- Kind: A1
- Application number: 15/687,692
- Filed: 2017-08-28
- Published: 2017-12-21
- Earliest claimed: 2012-06-06
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Universite Pierre Et Marie Curie (UPMC); Universite Paris Diderot—Paris 7; Universite Paris Descartes; Assistance Publique-Hopitaux de Paris
- Applicants: INSERM ( Institut National de la Sante et de la Recherche Medicale); Universite Pierre et Marie Curie UPMC; Universite Paris Diderot-Paris 7; Universite Paris Descartes; Assistance Publique-Hopitaux de Paris
- Inventors: Santos Susin; Pierre Launay; Philippe Karoyan; Helene Merle-Beral
- Web page: https://patentgrep.com/patent/US20170362302A1

## CPC

- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 7/06: having 5 to 11 amino acids
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

## Claims

### Claim 1

A method for treating cancer in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a soluble peptide comprising the amino acid sequence: KRFYVVMWKK (SEQ ID NO:1) or a function-conservative variant thereof.

### Claim 2 (depends on 1)

The method according to claim 1 wherein an amino acid sequence of the function-conservative variant differs from SEQ ID NO:1 by 1, 2 or 3 amino acids.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the soluble peptide consists of the amino acid sequence SEQ ID NO:1.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the cancer is a leukemia.

### Claim 5 (depends on 4)

The method according to claim 4 wherein the leukemia is B-chronic lymphocytic leukemia (CLL).

### Claim 6 (depends on 5)

The method according to claim 5 wherein the CLL is a refractory CLL.

### Claim 7 (depends on 1)

The method of claim 1, wherein said soluble peptide is administered by administering to said subject a nucleic acid encoding the soluble peptide.

### Claim 8 (depends on 1)

The method of claim 1, wherein said soluble peptide is administered by administering to said subject an expression vector comprising a nucleic acid encoding the soluble peptide.

### Claim 9 (depends on 1)

A The method of claim 1, wherein said soluble peptide is administered by administering to said subject a host cell comprising an expression vector comprising a nucleic acid encoding the soluble peptide.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising
i) at least one soluble peptide according to claim 1; or
ii) at least one acid nucleic encoding said at least one soluble peptide according to claim 1; or
iii) at least one expression vector comprising said at least one nucleic acid encoding said at least one soluble peptide according to claim 1; or
iv) at least one host cell comprising said at least one expression vector comprising said at least one nucleic acid encoding said at least one soluble peptide according to claim 1; and
a pharmaceutically acceptable carrier.

### Claim 11

A soluble peptide of formula (I):

### Claim 12

(canceled)

### Claim 13

A soluble peptide of formula (III):

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein said function-conservative variant is a soluble peptide of formula (II):

### Claim 16 (depends on 1)

The method of claim 1, wherein said function-conservative variant is a soluble peptide of formula (III):

### Claim 17 (depends on 1)

A method of treating cancer in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising
i) at least one soluble peptide according to claim 1; or
ii) at least one acid nucleic encoding at least one soluble peptide according to claim 1; or
iii) at least one expression vector comprising at least one nucleic acid encoding at least one soluble peptide according to claim 1; or
iv) at least one host cell comprising at least one expression vector comprising at least one nucleic acid encoding at least one soluble peptide according to claim 1; and
a pharmaceutically acceptable carrier.
